Skip to main content
NBIX logo

Neurocrine Biosciences, Inc. (NBIX) Stock: Price, Forecast & Analyst Target

Neurocrine Biosciences, Inc. (NBIX) — MoonshotScore 95/100 (Exceptional band), calculated Nov 18, 2026. Price $162.86 (-1.84%), as of the Nov 18, 2026 trading session; market cap $16.5B.

Educational signal · not a buy or sell recommendation · How to read this

$162.86 −$3.06 (-1.84%) Market Cap $16.5B

Neurocrine Biosciences, Inc. · NBIX · NASDAQ · Healthcare · Biotechnology

Research dated 2026-09-13: Neurocrine Biosciences is a profitable commercial-stage biotechnology company whose primary asset, INGREZZA, treats tardive dyskinesia, while partnered medicines and an internally developed pipeline broaden its reach across neurological, endocrine and psychiatric disorders. The case depends on whether INGREZZA-led product growth can continue funding heavier research and commercial investment without allowing earnings and cash conversion to lag behind sales.

Price as of Nov 18, 2026

Key Statistics

95 of 100

MoonshotScore v2 · Neurocrine Biosciences (NBIX)

Exceptional
Business Quality Elite (94)
Financial Safety Fortress (86)
Valuation Full (57)
Growth Durability Compounding (90)
Momentum Surging (82)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality, a strong balance sheet and elite growth, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Fortress; Valuation: Full; Growth Durability: Compounding; Momentum: Surging.

  • quarterly revenue $795M (Q3 FY2025, quarter ended Sep 2025)
  • EPS beat 6 of the last 8 reports
  • Altman Z 7.34 · Piotroski F 5

Helping: business quality, balance-sheet strength, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for NBIX (57 recorded, newest six shown)
RecordedScoreBand
93Exceptional
93Exceptional
93Exceptional
93Exceptional
95Exceptional
95Exceptional

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$162.86
Change on the day-1.84%
52-week range$122.14–$186.12
Market capitalisation$16.5B—
Price / earnings (trailing)23.80
Shares traded on the day1.60M
Beta (volatility vs the S&P 500)0.33

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 18, 2026: low $124, high $177, latest $163. $177 $124 high $177 Oct 17, 2025 Nov 18, 2026 · $163 $140Oct 17, 2025$143Oct 31, 2025$145Nov 14, 2025$152Nov 28, 2025$153Dec 12, 2025$145Dec 26, 2025$136Jan 9, 2026$136Jan 23, 2026$141Feb 6, 2026$129Feb 20, 2026$128Mar 6, 2026$128Mar 20, 2026$132Apr 2, 2026$133Apr 17, 2026$132May 1, 2026$158May 15, 2026$158May 29, 2026$160Jun 12, 2026$169Jun 26, 2026$177Jul 10, 2026$176Jul 24, 2026$163Aug 7, 2026$153Aug 21, 2026$156Sep 4, 2026$146Sep 18, 2026$143Oct 2, 2026$136Oct 16, 2026$146Oct 30, 2026$167Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Neurocrine Biosciences (NBIX): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Strong
Financial Safety Strong
Valuation Neutral
Growth Durability Strong
Momentum Strong

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Moderate
Margin of Safety Fairly Valued
Profit Margin Moderate
Revenue Growth Strong
Debt/Equity Moderate
ROE Strong
Gross Margin Strong

Read on: Nov 18, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company less favourably than the MoonshotScore does: Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Neurocrine Biosciences (NBIX), and what does it report?

Short answer · as of

Neurocrine develops and commercializes medicines rather than relying solely on clinical milestones or licensing payments.

INGREZZA is the main commercial asset, while ONGENTYS, ORILISSA and ORIAHNN extend the marketed portfolio and several experimental programs address epilepsy, depression, schizophrenia and related conditions through internal work and collaborations.

Reported revenue is overwhelmingly product revenue, with collaboration revenue contributing only a small remainder. The income statement therefore measures a functioning drug franchise alongside the cost of expanding the pipeline, not merely the progress of a precommercial biotechnology company.

2 · Latest results

What do the latest results show for Neurocrine Biosciences (NBIX)?

Short answer · as of

The most recent reported quarter, Q3 FY2025, carried revenue of $795M.

Recent revenue reached the highest level in the reported quarterly series and exceeded the prevailing estimate. Operating and net profit nevertheless declined from the preceding period, while diluted earnings fell short of expectations.

The financial statements show the immediate mechanism: research and development spending rose, and selling, general and administrative expense increased even more sharply. Management separately said its expense outlook now incorporates transaction and integration costs plus purchase-accounting effects, while also raising its patient-reach outlook for tardive dyskinesia and chorea associated with Huntington’s disease.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2025$795M$210M$2.04 (diluted)
Q4 FY2025$806M$154M$1.48 (diluted)
Q1 FY2026$815M$198M$1.91 (diluted)
Q2 FY2026$959M$144M$1.39 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Neurocrine Biosciences (NBIX)?

Short answer

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Neurocrine remains profitable and generates positive operating cash flow, with high gross margins, modest leverage relative to equity and strong distress-screen results. Capital expenditure is light beside operating cash generation, giving the commercial franchise meaningful capacity to support development spending.

The balance-sheet picture requires more care than the earnings line. Cash and short-term investments fell sharply across the reported window and ended near total debt, although additional long-term investments lift the broader cash-and-investment total above debt. Rising research and commercial costs could pressure margins further if product growth cools, while the recent cash movement makes acquisition, integration and other non-operating uses of funds important to track separately from operating performance.

4 · What to check next?

What should you watch next at Neurocrine Biosciences (NBIX)?

Short answer · as of

Current published price targets run low $165.00 · high $225.00 · consensus $203.41 · median $210.00 against a quoted price of $162.86 (as of Nov 18, 2026).

INGREZZA-led product revenue should be read alongside patient reach in tardive dyskinesia and Huntington’s disease chorea, because management tied its raised outlook to serving more patients in those indications. The scheduled earnings release also offers a direct test of whether revenue momentum is translating into operating profit after the recent jump in research and commercial expense.

Cash and investment movements deserve a separate check. The useful questions are whether operating cash generation remains positive, how transaction and integration costs develop, and whether the sharp reduction in short-term liquidity reflects continuing deployment or a stabilized balance-sheet position. Longer-range estimates assume continued expansion, but their wide revenue range makes execution more informative than the average forecast alone.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.
  • The newest quarter held here (Q3 FY2025) was filed Oct 28, 2025 — 12 months ago.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Neurocrine Biosciences compare with its peers?

Short answer

Neurocrine Biosciences's score ranks tied for 5th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Neurocrine differs from development-heavy biotechnology businesses because marketed medicines already produce substantial revenue, profit and operating cash flow. It also differs from broadly diversified pharmaceutical groups: product revenue is concentrated around a primary commercial asset even as the company funds a wide neurological and psychiatric pipeline and uses licensing partnerships to extend its portfolio.

That combination gives Neurocrine an established commercial engine and unusually high gross profitability, but it also links near-term financial performance closely to INGREZZA demand and the spending required to build future growth beyond that franchise.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Exelixis, Inc. (EXEL) Same industry, near in market value$68.29 Nov 18, 2026$16.7B98 5-pillar Nov 18, 2026
United Therapeutics Corporation (UTHR) Same industry, near in market value$577.34 Nov 18, 2026$24.6B97 5-pillar Nov 18, 2026
Ascendis Pharma A/S (ASND) Same industry, near in market value$270.33 Nov 18, 2026$17.7B96 5-pillar Nov 18, 2026
Krystal Biotech, Inc. (KRYS) Same industry, near in market value$315.34 Nov 18, 2026$9.34B96 5-pillar Nov 18, 2026
Neurocrine Biosciences (NBIX) — this page$162.86$16.5B95
Halozyme Therapeutics, Inc. (HALO) Same industry, near in market value$95.80 Nov 18, 2026$10.9B95 5-pillar Nov 18, 2026
Bio-Techne Corporation (TECH) Same industry, near in market value$72.75 Nov 18, 2026$11.4B92 5-pillar Nov 18, 2026
Incyte Corporation (INCY) Same industry, near in market value$117.80 Nov 18, 2026$24.0B91 5-pillar Nov 18, 2026
TG Therapeutics, Inc. (TGTX) Same industry, near in market value$66.12 Nov 18, 2026$9.99B90 5-pillar Nov 18, 2026
Smith & Nephew plc (SNN) Named competitor$30.32 Nov 18, 2026$12.7B84 5-pillar Nov 18, 2026
Alnylam Pharmaceuticals, Inc. (ALNY) Same industry, near in market value$149.40 Nov 18, 2026$20.0B72 5-pillar Nov 18, 2026
Genmab A/S (GMAB) Same industry, near in market value$50.97 Nov 18, 2026$31.4B72 5-pillar Nov 18, 2026
The Cooper Companies, Inc. (COO) Named competitor$60.75 Nov 18, 2026$11.6B40 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$165.00 – $225.00
Consensus target
$203.41
Median target
$210.00

Consensus record · Captured .

Measured against a quoted price of $162.86 (as of Nov 18, 2026).

Insider activity

Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Nov 4, 2026

Transactions
122
Identified insiders
20
Purchases
0
Sales
39
Other transactions
83

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held NBIX in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Bridgewater AssociatesFounded by Ray DalioQ3 20260.13%$29.27MHeld, unchanged

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Neurocrine Biosciences (NBIX)?

Read these with our analysis →

Neurocrine Biosciences Healthcare Stock: Key Questions Answered

The last 2 questions are answered from this page's own dated data, not from the research.

Why is INGREZZA so important to Neurocrine Biosciences?

INGREZZA is Neurocrine’s primary commercial asset, and product sales account for nearly all reported revenue. Its demand therefore supports current earnings and helps finance the broader clinical pipeline.

Why did Neurocrine’s profit fall while revenue rose?

Research spending increased and selling, general and administrative expense climbed sharply, more than offsetting the benefit of higher revenue. Management also incorporated transaction, integration and purchase-accounting effects into its expense outlook.

Does Neurocrine’s cash decline signal an operating burn problem?

The company continued producing positive operating cash flow, so the decline is not explained by operating burn alone. Recent acquisition activity and management’s transaction-cost guidance provide relevant context, while the broader investment balance makes the short-term cash figure an incomplete view of available financial resources.

What should investors watch in Neurocrine’s INGREZZA outlook?

Management linked its raised outlook to reaching more people with tardive dyskinesia or chorea associated with Huntington’s disease. Product revenue, patient reach and the expense required to support that growth should be evaluated together.

What is the NBIX stock price today?

The last price recorded for Neurocrine Biosciences, Inc. (NBIX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the NBIX price target?

The analyst consensus price target for Neurocrine Biosciences, Inc. (NBIX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 26 figures on this page — 1 from SEC filings and earnings calls, 21 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions)
  • 1. What is Neurocrine Biosciences (NBIX), and what does it report?: Business description; Revenue by segment; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands)
  • 2. What do the latest results show for Neurocrine Biosciences (NBIX)?: Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts; Recent SEC filings; Annual revenue and net result (USD millions)
  • 3. What are the financial strengths and risks for Neurocrine Biosciences (NBIX)?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Trailing twelve-month ratio set; Distress and quality screens; Management outlook — dated call excerpts; Recent SEC filings
  • 4. What should you watch next at Neurocrine Biosciences (NBIX)?: Management outlook — dated call excerpts; Next earnings report; Analyst revenue and earnings estimates (average); Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Cash and investment components; Recent SEC filings
  • 5. How does Neurocrine Biosciences compare with its peers?: Business description; Revenue by segment; Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set
  • FAQ: Why is INGREZZA so important to Neurocrine Biosciences?: Business description; Revenue by segment; Annual revenue and net result (USD millions)
  • FAQ: Why did Neurocrine’s profit fall while revenue rose?: Quarterly income statement (USD thousands); Management outlook — dated call excerpts; Recent SEC filings
  • FAQ: Does Neurocrine’s cash decline signal an operating burn problem?: Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Cash decline over the reported window; Cash and investment components; Recent SEC filings; Management outlook — dated call excerpts
  • FAQ: What should investors watch in Neurocrine’s INGREZZA outlook?: Management outlook — dated call excerpts; Revenue by segment; Quarterly income statement (USD thousands); Next earnings report
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.